How India Exports Ethambutol to the World

Ethambutol, a critical antitubercular agent, has been approved in the United States through multiple Abbreviated New Drug Applications (ANDAs). According to the FDA's Orange Book, numerous generic versions of ethambutol have received approval, indicating a well-established market presence. The most recent approval was granted in January 2026, reflecting ongoing interest and investment in this essential medication.

The importation of ethambutol into the U.S. is subject to stringent FDA regulations. As per the FDA's guidelines on importing human drugs, all foreign manufacturers must ensure compliance with Current Good Manufacturing Practices (cGMP) and register their facilities with the FDA. Additionally, the FDA maintains an import alert system to identify and restrict products that violate U.S. laws. As of March 2026, there are no active import alerts concerning ethambutol, suggesting that current imports meet the requisite regulatory standards.

Given that 97 Indian exporters are actively involved in the global ethambutol market, it is imperative for these entities to adhere to FDA regulations to maintain and expand their presence in the U.S. market.

In the European Union, ethambutol is subject to the European Medicines Agency's (EMA) centralized marketing authorization process or national procedures, depending on the specific product and applicant's strategy. The Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization in the United Kingdom. Both agencies require comprehensive data on quality, safety, and efficacy for approval.

Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for manufacturers supplying ethambutol to these markets. These standards ensure that products are consistently produced and controlled according to quality standards appropriate for their intended use.

Ethambutol is listed in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, underscoring its critical role in treating tuberculosis. The WHO's inclusion of ethambutol highlights its importance in global health initiatives. Additionally, ethambutol is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality benchmarks across different regions.

In India, ethambutol is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for ethambutol to ensure affordability; the latest revision was in December 2025. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to regulate and monitor the international trade of pharmaceuticals, including ethambutol.

The primary patents for ethambutol have expired, leading to a competitive generic market. This expiration has facilitated the entry of multiple manufacturers, contributing to the availability and affordability of the drug globally.

In August 2025, the WHO updated its Model List of Essential Medicines, reaffirming ethambutol's inclusion and emphasizing its continued relevance in tuberculosis treatment. In October 2025, the NPPA revised the ceiling price for ethambutol, reflecting efforts to balance affordability with industry sustainability. In January 2026, the FDA approved a new generic version of ethambutol, enhancing market competition and accessibility. In February 2026, the EMA issued updated guidelines on the manufacturing of antitubercular drugs, including ethambutol, to ensure compliance with evolving GMP standards. In March 2026, the CDSCO introduced streamlined procedures for the export NOC of pharmaceuticals, aiming to facilitate international trade while maintaining regulatory oversight.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on imports for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of India's APIs are sourced from China, highlighting a significant dependency on Chinese suppliers. This reliance poses substantial risks, as any disruption in the supply chain from China can directly impact India's pharmaceutical production capabilities.

The COVID-19 pandemic underscored these vulnerabilities, with supply chain disruptions leading to shortages of essential medicines. In response, the Indian government launched the Production Linked Incentive (PLI) scheme in 2020, allocating ₹6,940 crore to boost domestic production of 53 critical APIs and KSMs. Despite these efforts, the industry continues to face challenges in reducing its dependence on Chinese imports.

Our proprietary trade data from 2022 to 2026 reveals a high supplier concentration in the export of Ethambutol from India. The top five exporters account for 98.8% of total exports, with LUPIN LIMITED alone contributing 72.6% ($831.6M USD). This concentration indicates a significant single-source risk, as any operational or regulatory issues affecting these key suppliers could disrupt the global supply of Ethambutol.

The PLI scheme aims to mitigate such risks by encouraging diversification and enhancing domestic manufacturing capabilities. However, the effectiveness of this initiative in reducing supplier concentration remains to be fully realized.

Recent geopolitical tensions have further exacerbated supply chain vulnerabilities. In March 2026, the blockade of the Strait of Hormuz due to the U.S.–Iran conflict led to significant disruptions in global shipping routes. This blockade affected the transportation of pharmaceuticals and raw materials, causing delays and increased costs.

Additionally, tensions in the Red Sea and the Bab al-Mandab Strait have forced shipping companies to reroute vessels, adding transit times and escalating freight costs. These disruptions have had a cascading effect on the pharmaceutical supply chain, impacting the timely delivery of essential medicines. (lemonde.fr)

• Diversify API and KSM Sources: Encourage the development of alternative suppliers in different regions to reduce dependency on a single country.

• Strengthen Domestic Manufacturing: Accelerate the implementation of the PLI scheme to enhance local production capacities for critical APIs and KSMs.

• Enhance Supply Chain Transparency: Implement robust tracking systems to monitor the origin and movement of raw materials and finished products.

• Develop Contingency Plans: Establish strategic reserves and alternative logistics routes to mitigate the impact of geopolitical disruptions.

• Engage in International Collaboration: Work with global partners to create a more resilient and diversified pharmaceutical supply chain.

RISK_LEVEL: HIGH